2012版成人原发免疫性血小板减少症诊治的中国专家共识解读

秦平; 侯明

2012版成人原发免疫性血小板减少症诊治的中国专家共识解读

秦平,
侯明^,

- 山东大学齐鲁医院血液科(济南, 250012)
基金项目:
卫生公益性行业科研专项经费项目（No：201202017）；卫生部临床学科重点项目（No：2010-82）；国家自然科学基金（No：81070396）；山东省自然科学基金（No：ZR2009CM001）；山东省优秀中青年科学家奖励基金（No：BS2011YY020）

详细信息

通讯作者: 侯明,E-mail:houming@medmail.com.cn

中图分类号: R554

收稿日期: 2013-01-15

Corresponding author: , E-mail: houming@medmail.com.cn

Received Date: 15 January 2013

摘要

- 免疫性血小板减少症,原发性 /
- 诊断 /
- 治疗 /
- 共识 /
- 解读

HTML全文

参考文献(27)

[1]	RODEGHIERO F, STASI R, GERNSHEIMER T, et al.Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood, 2009, 113:2386-2393.
[2]	中华医学会血液分会血栓与止血学组.成人原发免疫性血小板减少症诊治的中国专家共识(修订版)[J].中华血液学杂志, 2011, 32(3):214-216.
[3]	OLSSON B, ANDERSSON P O, JERNAS M, et al.T-cellmediatedcytotoxicity toward platelets in chronicidiopathic thrombocytopenic purpura[J].Nat Med, 2003, 9:1123-1124.
[4]	MCMILLAN R, WANG L, TOMER A, et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood, 2004, 103:1364-1369.
[5]	LI S, WANG L, ZHAO C, et al.CD8⁺ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura[J].Br J Haematol, 2007, 139:605-611.
[6]	侯明, 纪春岩, 朱媛媛, 等.血小板减少性疾病患者血浆血小板生成素水平的检测[J].中华医学杂志, 1999, 85(5):356-357.
[7]	COHEN Y C, DJULBEGOVIC B, SHAMAI-LUBOVITZ O, et al.The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts[J].Arch Intern Med, 2000, 160:1630-1638.
[8]	王琳, 侯明.原发免疫性血小板减少症出血评分系统临床应用分析[J].中华血液学杂志, 2012, 33(6):499-501.
[9]	NEWTON J L, REESE J A, WATSON S I, et al.Fatigue in adult patients with primary immune thrombocytopenia[J].Eur J Haematol, 2011, 86:420-429.
[10]	THACHIL J, CALLAGHAN T, MARTLEW V.Thromboembolic events are not uncommon in patients with immune thrombocytopenia[J].Br J Haematol, 2010, 15:496-497.
[11]	秦平, 侯明, 孙建芝, 等.直接MAIPA对免疫性和非免疫性血小板减少性紫癜的鉴别诊断[J].中华血液学杂志, 2005, 26(3):167-169.
[12]	PROVAN D, STASI R, NEWLAND A C, et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood, 2010, 115:168-186.
[13]	NEUNERT C, LIM W, CROWTHER M, et al.The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J].Blood, 2011, 117:4190-4207.
[14]	PORTIELJE J E A, WESTENDORP R G J, KLUIN-NELEMANS H C, et al.Morbidity and mortality in adults with idiopathic thrombocytopenic purpura[J].Blood, 2001, 97:2549-2554.
[15]	CHENG Y, WONG R S, SOO Y O, et al.Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone[J].N Engl J Med, 2003, 349:831-836.
[16]	MAZZUCCONI M G, FAZI P, BERNASCONI S, et al.Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura:a GIMEMA experience[J].Blood, 2007, 109:1401-1407.
[17]	KOJOURI K, VESELY S K, TERRELL D R, et al.Splenectomy for adult patients with idiopathic thrombocytopenic purpura:a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications[J].Blood, 2004, 104:2623-2634.
[18]	RODEGHIERO F, STASI R, GERNSHEIMER T, et al.Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood, 2009, 113:2386-2393.
[19]	BUSSEL J B, PROVAN D, SHAMSI T, et al.Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura:a randomised, double-blind, placebo-controlled trial[J].Lancet, 2009, 373:641-648.
[20]	KUTER D J, BUSSEL J B, LYONS R M, et al.Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:a double-blind randomised controlled trial[J].Lancet, 2008, 371:395-403.
[21]	WANG S J, YANG R C, ZOU P, et al.A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J].Int J Hematol, 2012, 96:222-2228.
[22]	ARNOLD D M, DENTALI F, CROWTHER M A, et al.Systematic review:efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura[J].Ann Intern Med, 2007, 146:25-33.
[23]	GODEAU B, PORCHER R, FAIN O, et al.Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:results of a prospective multicenter phase 2 study[J].Blood, 2008, 112:999-1004.
[24]	PATEL V L, MAHÉVAS M, LEE S Y, et al.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood, 2012, 119:5989-5995.
[25]	ZAJA F, VOLPETTI S, CHIOZZOTTO M, et al.Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia[J].Am J Hematol, 2012, 87:886-889.
[26]	ZAJA F, VIANELLI N, VOLPETTI S, et al.Low-dose rituximab in adult patients with primary immune thrombocytopenia[J].Eur J Haematol, 2010, 85:329-334.
[27]	ZAJA F, BACCARANI M, MAZZA P, et al.Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia[J].Blood, 2010, 115:2755-2762.